Advanced Filters
noise

Charlestown, Massachusetts Clinical Trials

A listing of Charlestown, Massachusetts clinical trials actively recruiting patient volunteers.

Found 1,754 clinical trials
R Rita Mehta, MD

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer …

18 years of age All Phase 3
J Janice Wolfe

The GORE® VIAFORT Vascular Stent Iliofemoral Study

This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIAFORT Vascular Stent for treatment of symptomatic iliofemoral venous obstruction.

18 years of age All Phase N/A
R Robert M Richardson, MD, PhD

Computational Neuroscience of Language Processing in the Human Brain

Language is a signature human cognitive skill, but the precise computations that support language understanding remain unknown. This study aims to combine high-quality human neural data obtained through intracranial recordings with advances in computational modeling of human cognition to shed light on the construction and understanding of speech.

18 - 85 years of age All Phase N/A
A Ajay K. Gopal

Study of SGR-1505 in Mature B-Cell Neoplasms

The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

18 years of age All Phase 1
N Nadine J. McCleary, MD, MPH

Resilience and Equity in Aging, Cancer, and Health (REACH)

The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.

70 years of age All Phase N/A
J Jorge J. Castillo, MD

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

This study is being done to examine the safety and effectiveness of pirtobrutinib combined with venetoclax as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The names of the study drugs involved in this study are: Pirtobrutinib (a Noncovalent Bruton Tyrosine Kinase (BTK) inhibitor) Venetoclax (a BCL2 inhibitor)

18 years of age All Phase 2
G Guang-Shing Cheng, MD

BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)

The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS). The name of the study drugs involved in this study are: …

18 years of age All Phase 2

Using Transcranial Magnetic Stimulation (TMS) to Understand Hallucinations in Schizophrenia

This study uses a noninvasive technique called transcranial magnetic stimulation (TMS) to study how hallucinations work in schizophrenia. TMS is a noninvasive way of stimulating the brain, using a magnetic field to change activity in the brain. The magnetic field is produced by a coil that is held next to …

18 - 55 years of age All Phase N/A
G Gabriela Hobbs, MD

Ruxolitinib in Thrombocythemia and Polycythemia Vera

This research is being done to see if the drug ruxolitinib is effective in reducing the symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV). This research study involves the study drug Ruxolitinib.

18 years of age All Phase 2
S Stacey Ellender, PhD

Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.

21 years of age All Phase 2

Simplify language using AI